Category - Developments

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) and GE Healthcare agreed to a non-exclusive, worldwide license that will enable Profound to interface its TULSA-PRO system with certain GE Healthcare MRI scanners. The...

December 21, 2020

Developments

Albireo initiates Phase 3 Alagille syndrome trial

Albireo Pharma (NASDAQ:ALBO) launched a Phase 3 trial evaluating odevixibat for the treatment of Alagille syndrome, a rare genetic disorder that affects multiple parts of the body. Most Alagille patients present with...

December 17, 2020

Developments

Aldeyra initiates 3 Phase 2 trials of ADX-629

Aldeyra Therapeutics (NASDAQ:ALDX) launched three Phase 2 trials evaluating ADX-629 for the treatment of COVID-19, atopic asthma, and psoriasis. ADX-629 is an orally administered RASP inhibitor designed to modulate the...

December 17, 2020

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Developments

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D) failed to meet its primary endpoint. The trial enrolled 43 patients who were randomized to...

December 16, 2020

Developments

Durect gets FDA fast track designation for alcoholic hepatitis

Durect’s (NASDAQ:DRRX) DUR-928 received FDA fast track designation for the treatment of alcoholic hepatitis (AH), a life-threatening form of alcohol-associated liver disease. In August 2020, Durect reported results of...

December 16, 2020

Developments

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Eyenovia (NASDAQ:EYEN) announced that the first set of patients has been enrolled in the company’s Phase 3 VISION-1 study of MicroLine, a proprietary pilocarpine formulation delivered via its Optejet dispenser for the...

December 16, 2020

Developments

Verastem initiates Phase 2 non-small lung cancer trial

Verastem (NASDAQ:VSTM) initiated a Phase 2 registration-directed trial evaluating VS-6766 for the treatment of KRAS-G12V-mutant non-small cell lung cancer (NSCLC). In the first part of the study, VS-6766, a RAF/MEK...

December 15, 2020

Category - Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Albireo initiates Phase 3 Alagille syndrome trial

Aldeyra initiates 3 Phase 2 trials of ADX-629

Soricimed to investigate SOR-C13 to treat COVID-19

vTv Therapeutics azeliragon fails Phase 2 AD and T2D trial

Durect gets FDA fast track designation for alcoholic hepatitis

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Verastem initiates Phase 2 non-small lung cancer trial

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter